Cardiovascular disease (CVD) is the leading cause of premature mortality and morbidity in patients on haemodialysis (HD). Compared to the general population, patients on HD have a 5 – 30 fold increased risk of CVD, which accounts for about 50% of all-cause mortality.
The aim of SONG-HD Cardiovascular disease to develop a core outcome measure for cardiovascular disease to be included in all trials in patients requiring haemodialysis.
David Wheeler (Chair) | University College London, United Kingdom
Adeera Levin | University of British Columbia, Canada
Angela Wang | The University of Hong Kong, Hong Kong
Christoph Wanner |Universitätsklinikum Würzburg, Germany
Chuck Herzog |Hennepin County Medical Center, United States
Faiez Zannad | Université de Lorraine, France
Giovanni Strippoli | University of Bari, Italy
Jolanta Malyszko | Medical University of Bialystik, Poland
Marcello Tonelli | University of Calgary, Canada
Meg Jardine | The George Institute for Global Health, Australia
Michael Rocco | Wake Forest University, United States
Tazeen Jafar | Duke – National University Singapore, Singapore
Vera Krane |Universitätsklinikum Würzburg, Germany
Will Herrington | Oxford University, United Kingdom
Emma O’Lone (Project Coordinator) | The University of Sydney, Australia
1. Review of outcome measures for cardiovascular disease
A comprehensive review is now underway to identify, describe and evaluate all outcome measures that have been used for cardiovascular disease in clinical trials involving patients on haemodialysis.
An international online survey will be launched early 2017 to identify what cardiovascular outcomes are most important to patients, caregivers and health professionals.
3. SONG-HD Cardiovascular Disease Consensus workshop
Consensus workshops will be convened with patients, caregivers and health professionals to review and discuss potential core outcome measures for cardiovascular disease to be used in trials in haemodialysis.